Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.
Investors betting on the Principia short thesis face up to a clinical trial success that might not be what it seems.
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.